[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oncologic-complications\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oncologic-complications":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100434715","integrative-oncology-for-patient-symptoms-100434715",false,"NCT04940780","Integrative Oncology for Patient Symptoms","Examining the Impact of an Integrative Oncology Program on Patient Symptoms and Quality of Life: a Prospective Pragmatic Registry Protocol Study","Inclusion Criteria:\n\n* age ≥ 18 years\n* undergoing active oncology treatment\n* fully understand the study plan\n* agree to sign the study informed consent form.\n\nExclusion Criteria:\n\n* not fulfilling all of the study criteria\n* not interested in attending all 8 weekly CIM treatments sessions","ALL","18 Years",{"count":19,"type":20},750,"ESTIMATED","INTERVENTIONAL",[23],"NA","The use of complementary and integrative medicine (CIM) among oncology patients is widespread, with a large body of research-based evidence supporting the ability of these therapies to alleviate symptoms related to cancer and its treatment. Organizations such as the American Society for Clinical Oncology and the European Society for Medical Oncology have included CIM modalities in their treatment guidelines, and many of today's leading cancer centers include CIM in their supportive care service. The proposed study will prospectively examine the impact of a CIM treatment program on the symptom burden, quality of life and function of patients undergoing active oncology treatment.\n\nA total of 750 patients will undergo an integrative oncologist (IP) consultation followed by a series of 8 CIM treatments consisting of either acupuncture or touch-related therapies (reflexology, Shiatsu, Tuina, etc.) with the goal of relieving their symptoms. Patients will be allocated to one of the two study treatment arms: the \"Patient-Preference Arm\", for patients who specify their preference for either acupuncture or touch therapy; and the \"Randomized Treatment Arm\", for those with no preference, to be randomly allocated to either the acupuncture or touch-therapy subgroup. Patients will be asked to complete the following study questionnaires before and after the treatment regimen: the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30); the Edmonton Symptom Assessment System (ESAS); and the Measure Yourself Concerns and Wellbeing (MYCAW) tool. The primary study outcome will be the change in EORTC Global Health-Status \u002F Quality of Life scores, from pre- to post-treatment. Secondary study outcomes will include EORTC QLQ-C30 functional and symptom scales, single items assessing additional symptoms commonly reported by cancer patients, and perceived financial impact of the disease; ESAS severity scores for 10 quality-of life related items; and MYCAW severity scores for the 2 most significant symptoms, as well as post-treatment narratives. Other secondary outcomes to be assessed include the safety of the study treatments (adverse effects); adherence to conventional treatment regimen; and narratives from the patient's informal caregiver (spouse, parent\u002Fchild, sibling, friend, etc.).",[26,27],"Oncologic Complications","Symptoms and Signs",[29,30,31,32,33],"Integrative medicine","Integrative oncology","Acupuncture","Touch therapy","Wellbeing","RECRUITING","2026-04-23",{"date":37,"type":38},"2026-04-29","ACTUAL",{"date":40,"type":38},"2021-11-01",{"date":42,"type":20},"2027-12-31",{"name":44,"class":45},"Shaare Zedek Medical Center","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":5},"100493872","the-save-project-sarcopenia-and-vertigo-in-aging-patients-with-colorectal-cancer-100493872","NCT05710809","The SaVe Project-Sarcopenia and Vertigo in Aging Patients With Colorectal Cancer","SaVe","Inclusion Criteria:\n\n* Meet the criteria of the oncological departments of receiving neoadjuvant, adjuvant or first line palliative chemotherapy for colorectal cancer\n* ≥65 years of age at the time of signing the informed consent form\n* Able to speak and read Danish, and to provide a signed informed consent form\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status score of ≤2\n\nExclusion Criteria:\n\n* Chemotherapy treatment within two years and sequelae of neuropathy, or symptoms of dizziness or vertigo, or balance disturbance\n* Severe physical disability that hinders physical exercise\n* Dementia, psychotic disorders, or other cognitive diseases or conditions that hinder participation in a clinical exercise-based trial\n* Inability to sign informed content\n* Patients who have had a consultation in the geriatric outpatient clinic within the past six months","65 Years",{"count":56,"type":20},150,[23],"The goal of this clinical trial is to learn about the cause of dizziness and decline in walking ability in in older adults ≥65 years during chemotherapy treatment for colorectal cancer. Another goal is to investigate if a comprehensive geriatric assessment and three months' specialized physical group-based exercise three times\u002Fweek can counteract muscle weakness, vertigo, instability, impaired walking balance, and neuropathy",[60,26,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80],"Colorectal Cancer","Comprehensive Geriatric Assessment","Vestibular Rehabilitation","Geriatric Oncology","Sarcopenia","Vertigo","Cancer","Rehabilitation","Exercise","Geriatric","Elderly","Frail","Older Adults","Chemotherapy","Chemotherapy-induced Peripheral Neuropathy","Resistance Training","Balance Training","Postural Stability","Pragmatic Trial","Personal Medicine","Individualised","2025-04-02",{"date":83,"type":38},"2025-04-06",{"date":85,"type":38},"2023-02-20",{"date":87,"type":20},"2027-09",{"name":89,"class":45},"Rigshospitalet, Denmark"]